HC Wainwright reissued their buy rating on shares of Outlook Therapeutics (NASDAQ:OTLK – Free Report) in a report published on Friday, Benzinga reports. HC Wainwright currently has a $30.00 price target on the stock. HC Wainwright also issued estimates for Outlook Therapeutics’ Q1 2025 earnings at ($1.00) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 […]